

Updated: 05/19/2026

Click on the link below to be directed to study information at "ClinicalTrials.Gov" the US National Institutes of Health website.

Condition		Active Research Studies	St. Luke's Contact
<u>ANATOMICAL SITE</u>	<u>RESEARCH BASE & REFERENCE #</u>	<u>STUDY TITLE</u>	<u>ST. LUKE'S CONTACT</u>
<u>SMOKING CESSATION</u>	A211901 NCT05008848	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>MULTICANCER EARLY DETECTION</u>	Alliance A212102 NCT05334069	Blinded Reference Set for Multicancer Early Detection Blood Tests	Frances V. 218-249-5005 Cade M. 218-249-5647 ASL-Whiteside@aspirus.org
<u>BREAST GASTRIC/ABDOMINAL THORACIC</u>	iCaRe ²	Integrated Cancer Repository for Cancer Research	Frances V. 218-249-5005 Cade M. 218-249-5647 ASL-Whiteside@aspirus.org
<u>Breast Triple Negative</u>	Alliance A012103 NCT05812807	Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>Breast HR+ HER2-</u>	SWOG S2206 NCT0605837	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>PROSTATE</u>	NRG-GU010 NCT05050084	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>PROSTATE</u>	NRG-GU013 NCT05946213	Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>SKIN</u>	ECOG EA6174 NCT03712605	Pembrolizumab compared to Standard of Care Observation in Treating Patients with Completely Resected Stage I-III Merkel Cell Cancer	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>PANCREAS</u>	EA2192 NCT04858334	APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org

<u>NSCLC</u>	ARTEMIDE Lung-02 NCT06692738	A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1	Charity G. RN, 218-249-5177 Ahanna P. RN, 218-249-5581 ASL-Whiteside@aspirus.org
<u>NSCLC</u>	HARMONI7 NCT6767514	Summit HARMONI 7: A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression	Charity G. RN, 218-249-5177 Ahanna P. RN, 218-249-5581 ASL-Whiteside@aspirus.org
<u>NSCLC</u>	Andrometa NCT07155187	Andrometa: Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI	Ahanna P. RN, 218-249-5581 Charity G. RN, 218-249-5177 ASL-Whiteside@aspirus.org
<u>Hereditary Hemochromatosis</u>	FerrocLEAR NCT07332091	A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis	Charity G. RN, 218-249-5177 Ahanna P. RN, 218-249-5581 ASL-Whiteside@aspirus.org
<u>Pan Cancer</u>	Caris Biorepository NCT1499394	The Caris Biorepository Research Protocol	Ahanna P. RN, 218-249-5581 Charity G. RN, 218-249-5177 ASL-Whiteside@aspirus.org
<u>LEUKEMIA</u>	ReVenG NCT04895436	Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)	Charity G. RN, 218-249-5177 Ahanna P. RN, 218-249-5581 ASL-Whiteside@aspirus.org
<u>SOLID TUMORS WITH BRAF ALTERATIONS</u>	FORE8394 NCT02428712	A phase 2 trial to assess the efficacy and safety of plixorafenib, an inhibitor of BRAF class I and II alterations, in patients with BRAF alterations	Charity G. RN, 218-249-5177 Ahanna P. RN, 218-249-5581 ASL-Whiteside@aspirus.org

<u>Breast, Colorectal, Melanoma, non-Hodgkin Lymphoma, NSCLC</u>	Wake Forest, Alliance WF2304-A172401 NCT06418204	Assessing Benefits and Harms of Cannabis/ Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics (COSMIC)	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org
<u>Various</u>	EAY191 NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Cade M. 218-249-5647 Frances V. 218-249-5005 ASL-Whiteside@aspirus.org